Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
By L. Fabbri, P. Calverley, J. L. Izquierdo-Alonso, D. Bundschuh, M. Brose, F. Martinez, K. Rabe. The Lancet, 2009
621 citations recorded by the source corpus.
Subfields: Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/6378626587ace04c30d6b9a47467b294c4cab639
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pulmonary and Respiratory Medicine
- D. Parums
- P. Barnes
- R. Rodríguez-Roisín
- C. Jenkins
- Sonia Buist
- Jan Zieliński
- Yoshinosuke Fukuchi
- S. Hurd
Citations in the corpus
- Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. (2007, background): “A phosphodiesterase-4 inhibitor is effective when added to a long-acting bronchodilator (82), whereas evidence of its benefit when added to inhaled corticosteroid comes from less valid secondary analyses.”
- Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution (2023, positive): “Основным действием ингибиторов фосфодиэстеразы 4 является подавление воспаления путем блокирования распада внутриклеточной цАМФ [264, 265].”